Tectonic Therapeutic Inc (NASDAQ:TECX) has a beta value of 1.17 and has seen 1.18 million shares traded in the last trading session. The company, currently valued at $360.56M, closed the last trade at $24.44 per share which meant it lost -$16.74 on the day or -40.65% during that session. The TECX stock price is -118.54% off its 52-week high price of $53.41 and 50.41% above the 52-week low of $12.12. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.17 million shares traded. The 3-month trading volume is 124.06K shares.
The consensus among analysts is that Tectonic Therapeutic Inc (TECX) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
Tectonic Therapeutic Inc (NASDAQ:TECX) trade information
Sporting -40.65% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the TECX stock price touched $24.44 or saw a rise of 48.55%. Year-to-date, Tectonic Therapeutic Inc shares have moved -47.07%, while the 5-day performance has seen it change -40.94%. Over the past 30 days, the shares of Tectonic Therapeutic Inc (NASDAQ:TECX) have changed -51.66%. Short interest in the company has seen 0.57 million shares shorted with days to cover at 6.0.
Tectonic Therapeutic Inc (TECX) estimates and forecasts
Figures show that Tectonic Therapeutic Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 38.55% over the past 6 months, with this year growth rate of -425.95%, compared to 16.40% for the industry.
TECX Dividends
Tectonic Therapeutic Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Fidelity Advisor Biotechnology Fund . As of Sep 30, 2024 , the former fund manager holds about 2.59% shares in the company for having 381.59 shares of worth $9.33 million while later fund manager owns 142.6 shares of worth $3.49 million as of Nov 30, 2024 , which makes it owner of about 0.97% of company’s outstanding stock.
